MIAMI, FLORIDA / ACCESS Newswire / April 1, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing ...

In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key ...

Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis ...

Moving Biotech gets Health Canada approval to initiate phase 2a INFLAM MOTION clinical trial for knee osteoarthritis: Lille & Paris, France Saturday, March 29, 2025, 17:00 Hrs [I ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...

LILLE & PARIS, France--(BUSINESS WIRE)--4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatment that modify the natural history of knee osteoarthritis ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...

Q4 2024 Earnings Call Transcript March 27, 2025 BioRestorative Therapies, Inc. beats earnings expectations. Reported EPS is $ ...

BlackRock's recently posted CEO Larry Fink’s 2025 Annual Chairman’s Letter to Investors. Click here to read the full fund ...